Connor Clark & Lunn Investment Management Ltd. Has $6.70 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 145.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 214,864 shares of the specialty pharmaceutical company's stock after purchasing an additional 127,420 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.39% of Supernus Pharmaceuticals worth $6,699,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Commonwealth Equity Services LLC grew its holdings in shares of Supernus Pharmaceuticals by 3.6% during the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company's stock worth $273,000 after purchasing an additional 350 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock worth $61,000 after buying an additional 352 shares during the period. GAMMA Investing LLC grew its holdings in Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 398 shares during the last quarter. Louisiana State Employees Retirement System increased its position in Supernus Pharmaceuticals by 2.2% in the 2nd quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company's stock valued at $741,000 after acquiring an additional 600 shares during the period. Finally, Assetmark Inc. raised its stake in shares of Supernus Pharmaceuticals by 2.8% during the third quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company's stock valued at $1,043,000 after acquiring an additional 908 shares during the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 15,000 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the sale, the senior vice president now owns 8,200 shares of the company's stock, valued at approximately $303,236. This trade represents a 64.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Georges Gemayel sold 14,213 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the sale, the director now owns 13,315 shares of the company's stock, valued at approximately $487,595.30. This represents a 51.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 154,213 shares of company stock valued at $5,660,180 in the last quarter. 9.30% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Trading Up 1.1 %

SUPN stock traded up $0.40 during midday trading on Friday, hitting $36.22. The stock had a trading volume of 208,168 shares, compared to its average volume of 422,478. The business has a fifty day moving average price of $33.72 and a two-hundred day moving average price of $31.10. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.37. The firm has a market cap of $2.00 billion, a P/E ratio of 33.85 and a beta of 0.86.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.25. The company had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The firm's revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.29) EPS. On average, equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SUPN. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Piper Sandler reissued a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cowen reiterated a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.